In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
The industry rank for Panacea Life Sciences Holdings's Net-Net Working Capital or its related term are showing as below:
PLSH's Price-to-Net-Net-Working-Capital is ranked better than 91.08% of 415
companies
in the Drug Manufacturers industry
Industry Median: 7.76
vs PLSH: 1.25
Panacea Life Sciences Holdings (OTCPK:PLSH) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Panacea Life Sciences Holdings Net-Net Working Capital Related Terms
Panacea Life Sciences Holdings Net-Net Working Capital Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings Net-Net Working Capital Chart
PLSH vs SKYI, IMCC, CBDY: Net-Net Working Capital Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Life Sciences Holdings Price-to-Net-Net-Working-Capital vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Panacea Life Sciences Holdings's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.08 mean?
Panacea Life Sciences Holdings (PLSH) has a Net-Net Working Capital of $0.08 as of Sep. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Panacea Life Sciences Holdings According to the industry distribution chart, Panacea Life Sciences Holdings ranks #37 out of 415 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is Panacea Life Sciences Holdings' Net-Net Working Capital too high?
Panacea Life Sciences Holdings' current Net-Net Working Capital is $0.08. The Drug Manufacturers industry median Net-Net Working Capital is 7.76. Panacea Life Sciences Holdings' value of $0.08 is 99% below this industry median. Based on the distribution chart, Panacea Life Sciences Holdings ranks #37 out of 415 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Panacea Life Sciences Holdings has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Panacea Life Sciences Holdings' Net-Net Working Capital compare to SKYI and IMCC?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #37 out of 415 companies for Net-Net Working Capital. This places Panacea Life Sciences Holdings in the top 9% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 7.76. Panacea Life Sciences Holdings' value of $0.08 is 99% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Drug Manufacturers company?
The median Net-Net Working Capital among Drug Manufacturers companies is 7.76, based on 415 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Life Sciences Holdings's current Net-Net Working Capital of $0.08 is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Panacea Life Sciences Holdings For the Drug Manufacturers industry, the median Net-Net Working Capital is 7.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current Net-Net Working Capital is $0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current Net-Net Working Capital of $0.08. The current Net-Net Working Capital is $0.08 and 99% below the Drug Manufacturers industry median of 7.76. Panacea Life Sciences Holdings' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current Net-Net Working Capital is $0.08 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Panacea Life Sciences Holdings Business Description
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.
26GF Score
Get the complete analysis for PLSH
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSH has been successfully added to your 
